FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer (Q34004891)
scientific article
Language:
Current Data About FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer
(P31) (Q13442814)
(P248)
(P698) 17602060
(P813) Sunday, July 30, 2017

(P304) 713-718
(P248)
(P698) 17602060
(P813) Sunday, July 30, 2017

(P433) 6
(P248)
(P698) 17602060
(P813) Sunday, July 30, 2017

(P478) 12
(P248)
(P698) 17602060
(P813) Sunday, July 30, 2017

(P577) Friday, June 1, 2007
(P248)
(P698) 17602060
(P813) Sunday, July 30, 2017

(P921) (Q42214612)

(Q413299)
(P887)

(Q47912)
(P887)

(Q423762)
(P887)

(Q415588)
(P887)

(P1433) (Q2122327)
(P248)
(P698) 17602060
(P813) Sunday, July 30, 2017

(P1476) "FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer" (language: en)
(P248)
(P698) 17602060
(P813) Sunday, July 30, 2017

(P2093) Martin H Cohen
(P1545) 1
(P248)
(P698) 17602060
(P813) Sunday, July 30, 2017

Joe Gootenberg
(P1545) 2
(P248)
(P698) 17602060
(P813) Sunday, July 30, 2017

Patricia Keegan
(P1545) 3
(P248)
(P698) 17602060
(P813) Sunday, July 30, 2017

Richard Pazdur
(P1545) 4
(P248)
(P698) 17602060
(P813) Sunday, July 30, 2017

other details
description scientific article

External Links
(P356) 10.1634/THEONCOLOGIST.12-6-713
(P698) 17602060
(P5875) 6235631